Use of observational data in evaluating treatments: antiretroviral therapy and HIV. (Q30969932)

27 June 2017

1 reference

title

Use of observational data in evaluating treatments: antiretroviral therapy and HIV. (English)

1 reference

27 June 2017

Azra C Ghani

1

0 references

publication date

1 December 2003

1 reference

Expert Review of Anti-infective Therapy

27 June 2017

published in

1 reference

27 June 2017

volume

1

1 reference

27 June 2017

issue

4

1 reference

27 June 2017

page(s)

551-562

1 reference

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Workin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Randomized salvage therapy with saquinavir-ritonavir versus saquinavir-nelfinavir for highly protease inhibitor-experienced HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Time to hit HIV, early and hard.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Structured treatment interruptions in HIV infection: benefit or disappointment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Swiss HIV Cohort Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Natural history of HIV infection in the era of combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Decline in the AIDS and death rates in the EuroSIDA study: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Effect of ignoring the time of HIV seroconversion in estimating changes in survival over calendar time in observational studies: results from CASCADE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Mortality and progression to AIDS after starting highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Zidovudine and stavudine sequencing in HIV treatment planning: findings from the CHORUS HIV cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Attrition in longitudinal studies. How to deal with missing data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Impact of missing data due to selective dropouts in cohort studies and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Changing conditions and treatments in a dynamic cohort of ambulatory HIV patients: the HIV outpatient study (HOPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Patterns of antiretroviral use in the United States of America: analysis of three observational databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

Regional survival differences across Europe In HIV-positive people: the EuroSIDA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.4.551

21 January 2018

Identifiers

DOI

10.1586/14787210.1.4.551

1 reference

27 June 2017

1 reference